Who owns BioCryst Pharmaceuticals?

Key details on BioCryst Pharmaceuticals (Ticker: BCRX)

Who owns BioCryst Pharmaceuticals?

Is BCRX a good stock to own? Find out who bought BioCryst Pharmaceuticals, who sold BioCryst Pharmaceuticals (BCRX) stock, and who holds a large position in BioCryst Pharmaceuticals.

Fund Name Number of Shares Share Valuation As Of
Baker Bros. Advisors 10.71M $104.78M Sept. 30, 2014
FMR 10.65M $104.12M Sept. 30, 2014
RA Capital Management 7.07M $69.14M Sept. 30, 2014
Wellington Management Company 5.35M $68.20M June 30, 2014
BlackRock Fund Advisors 2.55M $24.92M Sept. 30, 2014
STATE STREET CORPORATION 2.33M $22.81M Sept. 30, 2014
D. E. Shaw & Co 2.09M $20.46M Sept. 30, 2014
Vanguard 2.07M $20.21M Sept. 30, 2014
BlackRock Institutional Trust Company, N.A. 1.93M $18.90M Sept. 30, 2014
VHCP Management 1.74M $17.06M Sept. 30, 2014
T. Rowe Price Associates 1.58M $16.75M March 31, 2014
TPG Group Holdings 1.16M $12.30M March 31, 2014
TPG Capital 1.16M $3.21M Sept. 30, 2011
Cormorant Asset Management 1.10M $10.76M Sept. 30, 2014
Deerfield Management Company 907920 $9.61M March 31, 2014
NORTHERN TRUST 841227 $8.23M Sept. 30, 2014
QVT Financial 725734 $7.10M Sept. 30, 2014
Driehaus Capital Management 702175 $2.98M Sept. 30, 2012
SUSQUEHANNA INTERNATIONAL 626000 $6.12M Sept. 30, 2014
Millennium Management 589752 $6.24M March 31, 2014
Connor, Clark & Lunn Investment Management 528098 $6.17M March 31, 2014
Barclays 516100 $2.49M March 31, 2012
Technical Financial Services 499516 $3.80M Dec. 31, 2013
MORGAN STANLEY 491034 $6.26M June 30, 2014
Charles Schwab Investment Management 450021 $4.40M Sept. 30, 2014
BOGLE INVESTMENT MANAGEMENT L P /DE/ 386089 $2.81M Sept. 30, 2013
Geode Capital Management 369040 $4.71M June 30, 2014
TIAA-CREF Investment Management 368154 $3.60M Sept. 30, 2014
BlackRock Advisors 344999 $3.37M Sept. 30, 2014
AQR Capital Management 343062 $3.36M Sept. 30, 2014
Jennison Associates 321422 $3.14M Sept. 30, 2014
Connor, Clark & Lunn Investment Management 316878 $2.56M Dec. 31, 2013
SMITH ASSET MANAGEMENT 302196 $468403 June 30, 2013
Thomson Horstmann & Bryant, Inc." 301529 $3.19M March 31, 2014

Who sold BioCryst Pharmaceuticals?

Fund Name Date Sold Number of Shares Sold Share Valuation
BAM Capital Dec. 31, 2010 861485 $4.45M